Interview 23 Jan 2023 Watch: pHion Therapeutics talks about next-generation mRNA vaccines pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […] January 23, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 New drug could replace current standard for treating brain cancer Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […] January 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 DeuterOncology closes financing round to start lung cancer study DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […] January 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy Brenus Pharma and InSphero AG have received a €1.5 million grant for the collaborative project “STC-1010: A First-in-Class Allogeneic Cell Vaccine Against Cancer,” which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer. Funding was provided by the Eurostars fund, a support mechanism for small and medium-sized enterprises under […] January 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Avacta completes fourth dose escalation in tumor study Avacta Group plc says that AVA6000 continues to show a favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumor biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumor tissue. This confirms the tumor targeting potential […] January 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […] January 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2023 BioInvent receives funding for blood cancer treatments BioInvent International AB has been selected as partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP). The program is aimed at advancing the company’s program to treat blood cancers. The partnership will include access to the scientific, clinical and drug development expertise of LLS as well as a strategic capital equity investment […] January 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2023 Funding for industry-first cancer screening technology Medicines Discovery Catapult (MDC) and SMi have secured a Biomedical Catalyst (BMC) grant to validate a new approach to detect cancer biomarkers. It will transform their use for routine cancer screening and enable monitoring of treatment efficacy in real time. Liquid biopsies are where a simple blood sample is analyzed for tiny quantities of cancer-related […] January 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Poolbeg expands POLB 001 into oncology Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023Beyond Biotech podcast 29: Janssen, Knowledge Gate This week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs, LLC. Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patients The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from […] January 12, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Anticancer drugs could lead to new sepsis treatment Researchers at the Instituto Gulbenkian de Ciência (IGC) in Oeiras, Portugal, say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis. The study, published in eLife, reveals that the class of drugs used in cancer treatment limit the unrestrained production of inflammatory mediators by the immune system. The discovery positions these […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email